WO2001016181A3 - Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands - Google Patents

Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands Download PDF

Info

Publication number
WO2001016181A3
WO2001016181A3 PCT/US2000/023744 US0023744W WO0116181A3 WO 2001016181 A3 WO2001016181 A3 WO 2001016181A3 US 0023744 W US0023744 W US 0023744W WO 0116181 A3 WO0116181 A3 WO 0116181A3
Authority
WO
WIPO (PCT)
Prior art keywords
ligands
receptor protein
tyrosine kinases
protein tyrosine
rptk
Prior art date
Application number
PCT/US2000/023744
Other languages
English (en)
Other versions
WO2001016181A2 (fr
Inventor
Joseph Schlessinger
Stevan B Hubbard
Moosa Mohammadi
Original Assignee
Univ New York School Medicine
Joseph Schlessinger
Stevan B Hubbard
Moosa Mohammadi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York School Medicine, Joseph Schlessinger, Stevan B Hubbard, Moosa Mohammadi filed Critical Univ New York School Medicine
Priority to EP00959577A priority Critical patent/EP1212365A2/fr
Priority to CA002382812A priority patent/CA2382812A1/fr
Priority to AU70870/00A priority patent/AU7087000A/en
Priority to US10/049,429 priority patent/US7129072B1/en
Priority to JP2001520740A priority patent/JP2003513016A/ja
Publication of WO2001016181A2 publication Critical patent/WO2001016181A2/fr
Publication of WO2001016181A3 publication Critical patent/WO2001016181A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne la détermination et l'utilisation de structures tridimensionnelles de protéines tyrosine kinases de récepteur (RPTK) et/ou de leurs ligands. Un groupe particulier de ces structures comprend des structures tridimensionnelles du domaine extracellulaire des RPTK. Les structures tridimensionnelles des RPTK peuvent faciliter la conception et l'identification de modulateurs de la fonction RPTK. D'autres structures de ce type peuvent comprendre des ligands RPTK, tels qu'un facteur de cellules souches ou un fragment de ce dernier. Les modulateurs de la fonction RPTK peuvent être utilisés pour traiter des maladies induites par une activité inappropriée de RPTK.
PCT/US2000/023744 1999-08-30 2000-08-30 Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands WO2001016181A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00959577A EP1212365A2 (fr) 1999-08-30 2000-08-30 Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands
CA002382812A CA2382812A1 (fr) 1999-08-30 2000-08-30 Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands
AU70870/00A AU7087000A (en) 1999-08-30 2000-08-30 Crystal structures of domains of receptor protein tyrosine kinases and their ligands
US10/049,429 US7129072B1 (en) 1999-08-30 2000-08-30 Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
JP2001520740A JP2003513016A (ja) 1999-08-30 2000-08-30 レセプタータンパク質チロシンキナーゼのドメイン、およびそのリガンドの結晶構造

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15181099P 1999-08-30 1999-08-30
US60/151,810 1999-08-30

Publications (2)

Publication Number Publication Date
WO2001016181A2 WO2001016181A2 (fr) 2001-03-08
WO2001016181A3 true WO2001016181A3 (fr) 2002-01-24

Family

ID=22540331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/023744 WO2001016181A2 (fr) 1999-08-30 2000-08-30 Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands

Country Status (5)

Country Link
EP (1) EP1212365A2 (fr)
JP (1) JP2003513016A (fr)
AU (1) AU7087000A (fr)
CA (1) CA2382812A1 (fr)
WO (1) WO2001016181A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002302640A1 (en) * 2001-06-07 2002-12-16 F. Hoffmann-La Roche Ag Mutants of igf binding proteins and methods of production of antagonists thereof
EP1585480A4 (fr) * 2003-01-21 2008-12-03 Smithkline Beecham Corp Co-cristal d'erbb4
US7303893B1 (en) 2003-08-28 2007-12-04 Takeda San Diego, Inc. Crystallization of c-KIT tyrosine kinase leading to autoinhibited crystal structure
JP5360738B2 (ja) * 2008-03-03 2013-12-04 国立大学法人 奈良先端科学技術大学院大学 細胞増殖促進活性を有するペプチド
CN104177492B (zh) * 2014-07-21 2017-02-22 暨南大学 FGFR2c胞外段类似物及其编码基因与应用
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
EP3583120B1 (fr) 2017-02-17 2022-10-05 Denali Therapeutics Inc. Polypeptides de liaison au récepteur de transferrine modifiés
EP3612234B1 (fr) 2017-04-20 2024-03-13 ADC Therapeutics SA Polythérapie avec un conjugué anticorps anti-axl-médicament
SI3665192T1 (sl) * 2017-08-10 2023-11-30 Denali Therapeutics Inc. Inženiring polipeptidov, ki se vežejo na receptorje za transferine
CN115746111A (zh) * 2021-09-02 2023-03-07 中国科学院天津工业生物技术研究所 一种转录调控因子LysG的突变体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007835A2 (fr) * 1996-08-21 1998-02-26 Sugen, Inc. Structures cristallines d'une proteine tyrosine kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007835A2 (fr) * 1996-08-21 1998-02-26 Sugen, Inc. Structures cristallines d'une proteine tyrosine kinase

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GIVOL DAVID ET AL: "Complexity of FGF receptors: Genetic basis for structural diversity and functional specificity.", FASEB (FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY), vol. 6, no. 15, 1992, 1992, pages 3362 - 3369, XP002167375, ISSN: 0892-6638 *
HUHTALA MIKKO T ET AL: "A dimeric ternary complex of FGFR1, heparin and FGF-1 leads to an 'electrostatic sandwich' model for heparin binding.", STRUCTURE (LONDON), vol. 7, no. 6, June 1999 (1999-06-01), pages 699 - 709, XP000993253, ISSN: 0969-2126 *
LIEKENS SANDRA ET AL: "Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds.", MOLECULAR PHARMACOLOGY, vol. 56, no. 1, July 1999 (1999-07-01), pages 204 - 213, XP000993567, ISSN: 0026-895X *
PELLEGRINI L ET AL: "The role of heparin in the complex formation between fibroblast growth factor 2 and its high affinity receptor: Comparative modelling and biochemical studies.", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 26, no. 3, August 1998 (1998-08-01), 665th Meeting of the Biochemical Society;Southampton, England, UK; March 31-April 2, 1998, pages 545 - 549, XP000993500, ISSN: 0300-5127 *
PELLEGRINI LUCA ET AL: "Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin.", NATURE (LONDON), vol. 407, no. 6807, 2000, pages 1029 - 1034, XP002167378, ISSN: 0028-0836 *
PLOTNIKOV ALEXANDER N ET AL: "Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity.", CELL, vol. 101, no. 4, 12 May 2000 (2000-05-12), pages 413 - 424, XP002167377, ISSN: 0092-8674 *
PLOTNIKOV ALEXANDER N ET AL: "Structural basis for FGF receptor dimerization and activation.", CELL, vol. 98, no. 5, 3 September 1999 (1999-09-03), pages 641 - 650, XP002167376, ISSN: 0092-8674 *
STAUBER DEBORAH J ET AL: "Structural interactions of fibroblast growth factor receptor with its ligands.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 1, 4 January 2000 (2000-01-04), Jan. 4, 2000, pages 49 - 54, XP002167379, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1212365A2 (fr) 2002-06-12
CA2382812A1 (fr) 2001-03-08
JP2003513016A (ja) 2003-04-08
WO2001016181A2 (fr) 2001-03-08
AU7087000A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
ATE510957T1 (de) Enzyme geeignet zum ändern der eigenschaften von polyester
DE69828408D1 (de) Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
ATE251942T1 (de) Stapelbare statische mischelemente
WO2003050295A3 (fr) Essais et mises en oeuvre permettant de determiner et de moduler une activite de liaison hsp90
WO2003024388A3 (fr) Methodes et compositions de traitement ou de prevention de troubles cutanes au moyen d'agents de liaison specifiques pour un antigene membranaire specifique de la prostate
WO2005113596A3 (fr) Isoformes de recepteurs de la surface cellulaire et methodes d'identification et d'utilisation de ces derniers
ATE413386T1 (de) Ppar-gamma modulatoren
EP2679235A3 (fr) Peptides et molécules associées qui modulent l'activité du facteur de croissance nerveuse
DE69732711D1 (de) Gamma-heregulin
WO2001083755A3 (fr) Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation
WO2001016181A3 (fr) Structures cristallines de domaines de proteines tyrosine kinases de recepteur et de leurs ligands
WO2001078703A3 (fr) Methodes et compositions destinees a moduler l'activite des recepteurs adrenergiques alpha
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
WO2004081229A3 (fr) Compositions a activite hematopoietique et immunitaire
EP0854185A3 (fr) Protéines réceptrices pour dépistage et ligands
TR200003622T2 (tr) Zayıflatılımış Pestivirüsler.
IL149416A0 (en) Human enzymes of the metalloprotease family
WO2004012673A3 (fr) Methodes et reactifs relatifs a l'inflammation et a l'apoptose
AU2813200A (en) Assay for measuring different enzyme activities simultaneously
WO2004017992A3 (fr) Proteine impliquee dans le carcinome
EP0714982A3 (fr) Protéines hybrides, ayant des propriétés fibrinolytiques et inhibant la thrombine
WO2002076507A3 (fr) Utilisations de ligands d'osteoprotegerine (opg) pour la modulation de reponses immunitaires
ATE383374T1 (de) Verwendung der extrazellulären domäne von trade molekülen in medikamenten zur behandlung von neoplasie
WO2000073333A3 (fr) Ligand pour cd7 et procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2382812

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 520740

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000959577

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000959577

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10049429

Country of ref document: US